Preclinical studies have demonstrated that GLP-1 receptor agonists reduce neuroinflammation, reduce tau phosphorylation, reduce amyloid deposition, increase synaptic function, and improve memory formation
Subcut, Subcutaneous injection
Patients receiving semaglutide (0.5 or 1.0 mg) for 104 weeks demonstrated a significantly higher risk of diabetic retinopathy complications, including vitreous hemorrhage, blindness, or required procedural treatment compared to those receiving placebo (HR, 1.76
For plots c, d, and e, point estimates are represented as circles, and horizontal bars indicate 95% confidence intervals
"Advanced Nano-Delivery Matrix" - Brand-stated technology description
Those With Weight Management Goals GLP-1 shots have been shown to aid in weight management by promoting feelings of fullness and reducing appetite